INTRODUCTION
============

Colorectal cancer is the third most common malignancy in South Korea, and its annual associated age-standardized cancer mortality and incidence rates are increasing \[[@b1-ac-2018-10-18-2]\]. The current standard of surgery for mid- to low-rectal cancer is total mesorectal excision (TME) with radical resection of the rectum. TME in rectal cancer has led to dramatic improvements in the local recurrence (LR) rate and anal sphincter preservation \[[@b2-ac-2018-10-18-2]\]. However, TME has some disadvantages that are associated with radical resection, including longer surgical times and higher morbidity and mortality, and it also is associated with a greater risk of loss of anorectal function \[[@b3-ac-2018-10-18-2]\].

Transanal excision (TAE) is a procedure that involves local excision for benign and malignant rectal neoplasms. TAE can be performed to identify pathology or for local control of benign and early rectal malignancy without the risk of lymph node metastasis. Because there is a 10%--15% risk of lymph node metastasis for T1 rectal cancer, TAE should be considered only for selected patients that do not have a risk of lymph node metastasis, regardless of anorectal function \[[@b4-ac-2018-10-18-2]\].

In the present study, we reviewed patients with pathologically confirmed T1 rectal cancer who underwent TAE and TME and compared the long-term outcomes of the 2 groups in terms of survival and recurrence.

METHODS
=======

Patients
--------

Data from pT1 rectal adenocarcinoma patients who underwent surgery from January 1990 to December 2011 were retrospectively reviewed. The data included age, sex, lesion size, distance from the anal verge, serum carcinoembryonic antigen (CEA) level, histology type and grade, lymphovascular invasion, depth of invasion, and adjuvant therapy. Exclusion criteria were: (1) preoperative suspicion of lymph node metastasis, (2) age greater than 79 years or less than 19 years, (3) upper rectal cancer, i.e., a lower tumor border located 10 cm or more proximally from the anal verge, (4) noncurative surgery (R1 or R2), (5) preoperative chemoradiation, (6) pathology other than adenocarcinoma, (7) recurrent or metastatic cancer, (8) unclear pathologic data, including depth of tumor or lymphovascular invasion, and (9) less than 6 months of follow-up. This study was approved and was exempted from informed consent by the Institutional Review Board of the Asan Medical Center (approval number: 2018-1135).

Transanal excision
------------------

The indications and detailed procedures for TAE in our institution were described in our previous study \[[@b5-ac-2018-10-18-2]\]. Indications for TAE include a small (less than 3 cm), movable, palpable with index finger and well to moderately differentiated tumor. The tumor should be at the T1 stage without invading more than 30% of the rectal circumference and without lymph node metastasis on preoperative transrectal ultrasonography, computerized tomography, or magnetic resonance imaging.

Patients had 4 L of polyethylene glycol orally on the day before surgery and fasted from midnight. Surgery was performed under either general or spinal anesthesia. A urinary catheter was inserted after the anesthesia, and the patient's position was changed to a prone jack-knife position. After dilation and adequate traction of the anal canal, the tumor was identified and excised under direct vision at full thickness with margins of at least 0.5 cm. The rectal wall defect was repaired with absorbable sutures. A single surgical instrument used for transendoscopic microsurgery has not been identified at our institution. Cases of transanal minimally invasive surgery were not included due to the heterogeneity of the procedure and scarcity of cases.

Definitions
-----------

Patients were placed into a TAE or a TME group, depending on the procedure. Five patients that underwent TAE followed by TME because of adverse histologic findings were included in the TME group. Distance from anal verge was dichotomized at under or over 5 cm from the anal verge, which divides the low rectum from the mid rectum \[[@b6-ac-2018-10-18-2]\]. Tumor size was dichotomized at ≥3 cm or \<3 cm \[[@b7-ac-2018-10-18-2]\]. The threshold for elevated serum CEA was 6 ng/mL, which is the normal limit at our institution. The depth of invasion into the submucosa was classed as sm1 (upper third), sm2 (middle third), and sm3 (lower third) for sessile tumors (n = 254) \[[@b8-ac-2018-10-18-2]\]. Pedunculated lesions (n = 14) were categorized by Haggitt level \[[@b9-ac-2018-10-18-2]\]. Haggitt levels 3--4 and sm2--3 were grouped as deep submucosal invasions \[[@b4-ac-2018-10-18-2], [@b10-ac-2018-10-18-2]\]. The favorable histology group had well-differentiated or moderately differentiated adenocarcinomas, whereas the unfavorable histology group contained poorly differentiated or mucinous adenocarcinomas \[[@b5-ac-2018-10-18-2], [@b11-ac-2018-10-18-2]\]. The risk factors for lymph node metastasis were: defined tumors with any type of deep submucosal invasion, lymphovascular invasion, and unfavorable histology. Recurrence included LR, systemic recurrence, and both recurrences concomitantly.

Follow-up
---------

Patients received standardized postoperative follow-up, including clinical examinations, complete blood counts, blood chemistry tests, serum CEA quantitation, and chest radiography, every 6 months for the first 2 years postoperatively and every 12 months thereafter. They also underwent abdominal and pelvic computed tomography (CT) scanning and transrectal ultrasound (TUS) every 12 months. Colonofiberoscopy or sigmoidofiberoscopy was performed every 6 months after the first postoperative year and then annually thereafter. Patients with suspected recurrence had individualized examinations including specific imaging work-up (e.g., TUS, CT, magnetic resonance imaging, and/or positron emission tomography) or biopsy. Survival status and date of death were confirmed by follow-up data.

Adjuvant therapy
----------------

Adjuvant chemoradiation therapy was considered in cases within the TME group with lymph node metastasis and within the TAE group that exhibited sm2 or sm3, lymphovascular invasion, unfavorable histologic findings, or close resection margins. Radiation therapy was delivered by a linear accelerator (Clinac 1800 instrument; Varian Medical Systems, Palo Alto, CA, USA). Patients were instructed to lie in a prone position, and 6 to 15 MV of radiation was applied through 3 or 4 fields to the pelvis. Patients were irradiated with 2 Gy, 5 days a week, for a total dose of 50 Gy. The superior border for irradiation was the bottom edge of the fifth lumbar vertebra, and the inferior border was 3 cm caudal to the tumor. The lateral borders were 1.5 to 2.0 cm medial from the inner bony margin of the most lateral portion of the true pelvis. The anterior border was 3 cm ventral to the tumor, and the posterior border was 1 cm from the dorsal margin of the sacrum. The primary tumor, regional lymph nodes, and perirectal fat tissue were included in the target volume \[[@b5-ac-2018-10-18-2]\].

Analysis
--------

Data were reported as mean ± standard deviation for continuous variables and as frequency (%) for categorical variables. Univariate analyses were conducted to compare patient characteristics of the TAE and TME groups. Pearson chi-square test or Fisher exact test were used for categorical data, and the Student t-test was used for continuous data. The LR, recurrence-free survival (RFS), overall survival (OS), and cancer-specific survival (CSS) rates were calculated using the Kaplan-Meier method, and the log-rank test was used to compare differences among survival curves in univariate analyses. The potential prognostic factors that were screened in univariate analysis were further analyzed by multivariate analysis using a Cox regression model, and hazard ratios (HRs) were calculated with 95% confidence intervals (CIs). A P-value of \<0.05 was considered statistically significant for all analyses, and all calculations were carried out using IBM SPSS Statistics ver. 24.0 (IBM Co., Armonk, NY, USA).

RESULTS
=======

Patient characteristics
-----------------------

Of the 268 pathologic T1 rectal cancer patients, 61 (22.8%) underwent TAE and 207 (77.2%) underwent TME. The TAE group was characterized by tumors that were closer to the anus (P \< 0.001), more frequent deep submucosal invasion lesions (P = 0.02), and more frequently infiltration (P = 0.033). Thirty-two patients (52.5%) in the TAE group had risk factors for lymph node metastasis, which was less frequent than for the TME group (P = 0.013) ([Table 1](#t1-ac-2018-10-18-2){ref-type="table"}). There were no differences between the groups in age, sex ratio, tumor size, lymphovascular invasion, tumor differentiation, and serum CEA level.

Survival and recurrence
-----------------------

The follow-up period had a median of 10.4 years (range, 1.6--20.6 years), and the 10-year OS rate for TAE patients was not different from the TME group (91% vs. 90%) ([Table 2](#t2-ac-2018-10-18-2){ref-type="table"}). The 10-year CSS rate for TAE was slightly lower than for the TME group (98% vs. 100%), although this result was not statistically significant (P = 0.22) ([Fig. 1](#f1-ac-2018-10-18-2){ref-type="fig"}). There was no difference in the 10-year OS and CSS rates for lymph node metastasis risk factors ([Table 2](#t2-ac-2018-10-18-2){ref-type="table"}).

Twelve patients had systemic and/or LR, which are described in [Table 3](#t3-ac-2018-10-18-2){ref-type="table"}. In total, 75% of recurrence cases (n = 9) developed within 5 years postoperatively. The 10-year RFS rate for TAE was lower than that for TME (86% vs. 99%, P \< 0.001). A TAE surgical procedure was the only independent risk factor for recurrence (HR, 6.8; 95% CI, 2.0--22.5; P = 0.002) ([Table 4](#t4-ac-2018-10-18-2){ref-type="table"}).

The 10-year LR rate for TAE was greater than for TME (10% vs. 0%, P \< 0.001) ([Fig. 2](#f2-ac-2018-10-18-2){ref-type="fig"}). Among patients with risk factor for lymph node metastasis, the 10-year LR rate for TAE was 16% compared to 1% of TME (P \< 0.001) ([Table 2](#t2-ac-2018-10-18-2){ref-type="table"}). Of the 5 TAE patients with LR, four had salvage surgery but one of the patients eventually died. The patient that did not undergo salvage surgery was lost to follow-up immediately after confirmation of recurrence. The median time from initial surgery to salvage surgery was 18 months, and the mean survival after LR was 12 years. The TAE surgical procedure (HR, 19.1; 95% CI, 2.3--159.8; P = 0.007) was the only independent risk factor for LR ([Table 5](#t5-ac-2018-10-18-2){ref-type="table"}).

DISCUSSION
==========

For the past two decades, TAE has been used as a potential alternative to TME in patients with early rectal cancer. Although there have been many reports on TAE, few studies have been conducted in South Korea \[[@b7-ac-2018-10-18-2], [@b12-ac-2018-10-18-2]\]. The present study is significant because of a long-term follow-up of more than 10 years and the relatively large number of patients from a single tertiary referral center. Our major finding was that TAE results in a higher LR than TME, which was consistent with the results of previous studies \[[@b7-ac-2018-10-18-2], [@b13-ac-2018-10-18-2]\]. However, the elevated LR rate from TAE was not associated with poor long-term survival, compared with TME. These survival outcomes could be attributable to the relatively low incidence of LR in patients in this study, and the high frequency of salvage treatment upon LR.

The National Comprehensive Cancer Network guidelines are one of the most widely used recommendations in rectal cancer. Version 1.2018 for rectal cancer suggests criteria for TAE based on a study by Nash and colleagues \[[@b7-ac-2018-10-18-2], [@b14-ac-2018-10-18-2]\]. The recommendations suggest that patients who have not experienced an endoscopically-removed polyp with cancer or indeterminate pathology can be candidates for TAE if the T1 tumors are under 3 cm and without lymph node metastasis, mobile, nonfixed and well- to moderately differentiated and within 8 cm of the anal verge with less than 30% of bowel invasion, and without lymphovascular invasion or perineural invasion. Full-thickness excision and a clear resection margin of over 3 mm should be confirmed. In the present study, most TAE patients fell within this guideline; however, some patients that did not meet these criteria were indicated for radical resection or adjuvant therapy.

The 5-year LR rate in the TAE group (10%) was not significantly different compared with the 7% to 17% reported in previous studies \[[@b12-ac-2018-10-18-2], [@b15-ac-2018-10-18-2], [@b16-ac-2018-10-18-2]\]. However, the TME group had an extremely low 5-year LR rate (0%), which was better than the results of other studies (2%--6%) \[[@b12-ac-2018-10-18-2], [@b13-ac-2018-10-18-2]\]. In addition, the 5-year OS rates for TAE (95%) and TME (97%) in this study were better than those in previous reports (72%--89% for TAE and 80%--93% for TME) \[[@b13-ac-2018-10-18-2], [@b15-ac-2018-10-18-2], [@b17-ac-2018-10-18-2]\]. One possible explanation for these favorable outcomes is a lower frequency of unfavorable histology (1.5%) compared with other studies (5.3%--12.1%) \[[@b7-ac-2018-10-18-2], [@b12-ac-2018-10-18-2]\]. Another reason could be our exclusion of patients that were suspected to have lymph node metastasis. In addition, the effect of LR on long-term survival is still controversial. Some studies have shown a poorer survival after TAE because of high LR \[[@b7-ac-2018-10-18-2], [@b13-ac-2018-10-18-2], [@b15-ac-2018-10-18-2]\]. However, this study did not find a significant difference in OS as well as CSS, which is consistent with Bentrem et al. \[[@b17-ac-2018-10-18-2]\]. This trend could be attributed to the use of appropriate treatments, such as adjuvant chemoradiation therapy or salvage surgery.

Radiation therapy after local excision significantly improved 5-year local control in high-risk patients with pT1 rectal cancer (89% vs. 100%) \[[@b18-ac-2018-10-18-2]\]. In another study of TAE in pT1 and pT2 patients, radiation therapy did not reduce overall recurrence but delayed LR (median 2.1 years with radiation vs. 1.1 years without radiation) \[[@b19-ac-2018-10-18-2]\]. A previous retrospective study of local excision at our institution revealed no difference in RFS rate based on radiation therapy \[[@b20-ac-2018-10-18-2]\]. Even if LR occurs after TAE, salvage surgery is a possibility for a significant number of cases and favorable OS outcomes are associated with appropriate salvage surgery. A previous investigation showed good outcomes in all six patients that received salvage surgery for LR, who were still alive at follow-up at 57 months \[[@b16-ac-2018-10-18-2]\]. In another study, 16 patients underwent salvage surgery, but 7 of the patients died \[[@b7-ac-2018-10-18-2]\]. Our four patients who had LR underwent salvage surgery and their 5-year OS rate was 60%, which was comparable to the 50%--58% reported in other studies \[[@b17-ac-2018-10-18-2], [@b21-ac-2018-10-18-2]\].

Lymphovascular invasion \[[@b12-ac-2018-10-18-2], [@b22-ac-2018-10-18-2]\], unfavorable histology \[[@b12-ac-2018-10-18-2]\], and depth of submucosal invasion \[[@b15-ac-2018-10-18-2]\] have been recognized as risk factors for recurrence after both TAE and TME. Although we could not identify any independent risk factors, other than the type of operation, these risk factors for lymph node metastasis were associated with a higher probability of LR for the TAE group in this study (HR, 5.797; 95% CI, 1.1--31.7; P = 0.043). Therefore, patients with any risk factors should be considered for TME to optimize oncologic outcomes.

There were several limitations to this study. Because this was a single-center study, the results may not be externally validated and may differ to studies with different populations and in different settings \[[@b23-ac-2018-10-18-2]\]. Most importantly, since this was a retrospective study, the reasons for patients receiving TAE alone or in conjunction with radiation therapy or chemotherapy are unknown. A selection bias of procedure groups should also be considered because our TAE group had tumors with smaller sizes and that were closer to the anal verge. Therefore, it may have been more difficult to control for confounding variables and unmeasured parameters or misclassifications may have influenced survival \[[@b24-ac-2018-10-18-2]\].

In conclusion, TAE results in a greater risk of recurrence than TME, although long-term survival was comparable between the 2 procedures. Thus, TAE should only be considered for carefully selected patients as an alternative surgical option for early rectal cancer.

No potential conflict of interest relevant to this article was reported.
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###### 

Clinicopathologic characteristics

  Variable                        Total (n = 268)   TAE (n = 61)   TME (n = 207)   P-value
  ------------------------------- ----------------- -------------- --------------- ---------
  Age (yr)                        58.8 ± 9.6        58.0 ± 9.5     59.0 ± 9.6      0.290
  Female sex                      117 (43.7)        28 (45.9)      89 (43.0)       0.770
  Distance from anal verge (cm)   6.2 ± 2.6         4.1 ± 2.0      6.8 ± 2.4       \<0.001
  Tumor size ≥3 cm                54 (22.5)         8 (15.7)       46 (24.3)       0.260
  Lymph node metastasis                                            15 (7.3)        
   Deep submucosal invasion       174 (64.9)        32 (52.5)      142 (68.6)      0.020
   Lymphovascular invasion        30 (11.2)         4 (6.6)        26 (12.6)       0.250
   Unfavorable histology          4 (1.5)           2 (3.3)        2 (1.0)         0.224
   Elevated CEA                   5 (1.9)           3 (5.1)        2 (1.0)         0.078
  Growth type                                                                      0.033
   Expanding                      194 (78.9)        45 (90.0)      149 (76.0)      
   Infiltrative                   52 (21.1)         5 (9.6)        47 (24.0)       
  With risk factor                176 (42.9)        32 (52.5)      144 (69.6)      0.013
  Chemotherapy                    48 (17.9)         10 (16.4)      38 (18.4)       0.850
  Radiation therapy               28 (10.4)         18 (29.5)      10 (4.8)        \<0.001

Values are presented as mean ± standard deviation or number (%).

TAE, transanal excision; TME, total mesorectal excision; CEA, carcinoembryonic antigen.

Deep submucosal invasion included sm^2^--3 for sessile tumor and Haggitt level 3--4 for pedunculated tumor.

###### 

Long-term oncologic outcomes

  Outcome                        5 Years   10 Years   P-value         
  ------------------------------ --------- ---------- --------- ----- ---------
  Overall survival (%)           95        97         91        90    0.910
   Without risk factor           97        100        96        94    0.680
   With risk factor              94        96         90        88    0.890
  Cancer-specific survival (%)   98        100        98        100   0.220
   Without risk factor           100       100        100       100   0.220
   With risk factor              97        99         97        99    0.320
  Recurrence-free survival (%)   90        99         86        99    \<0.001
   Without risk factor           96        100        93        100   0.038
   With risk factor              84        98         80        97    0.001
  Local recurrence rate (%)      10        0          10        0     \<0.001
   Without risk factor           4         0          4         0     0.140
   With risk factor              16        1          16        1     \<0.001

TAE, transanal excision; TME, total mesorectal excision.

Risk factors included deep submucosal invasion, lymphovascular invasion, and poor histology results.

###### 

Recurrence patterns and treatment approaches

  Sex   Age   Recurrence type   Operation   Salvage surgery   Last status   Recurrence-free survival (mo)   Survival after recurrence (mo)   Adjuvant therapy after recurrence
  ----- ----- ----------------- ----------- ----------------- ------------- ------------------------------- -------------------------------- -----------------------------------
  F     35    LR                TAE         Yes               Alive         44                              46                               CTx + RTx
  F     47    LR                TAE         Yes               Dead          20                              96                               CTx + RTx
  F     48    LR                TAE         No                Alive         58                              0                                No
  F     62    LR                TAE         Yes               Alive         14                              161                              No
  F     63    LR                TAE         Yes               Alive         39                              103                              CTx + RTx
  M     53    SR                TAE         No                Dead          115                             79                               CTx + RTx
  F     46    SR                TAE         Yes               Dead          86                              38                               CTx
  F     59    LR + SR           TAE         No                Dead          21                              10                               CTx
  M     49    LR                TME         Yes               Alive         8                               109                              CTx + RTx
  M     63    SR                TME         No                Dead          84                              51                               No
  F     54    SR                TME         Yes               Alive         9                               161                              CTx + RTx
  M     54    SR                TME         Yes               Dead          5                               16                               CTx

LR, local recurrence; SR, systemic recurrence; TAE, transanal excision; TME, total mesorectal excision; CTx, chemotherapy; RTx, radiation therapy.

###### 

Univariate and multivariate analyses of recurrence

  Variable                  Univariate analysis   Multivariate analysis                                   
  ------------------------- --------------------- ----------------------- ------- ------- --------------- -------
  Sex                                                                                                     
   Male                     1.000                                                                         
   Female                   2.661                 0.801--8.839            0.110                           
  Operation type                                                                                          
   TME                      1.000                                                 1.000                   
   TAE                      6.759                 2.035--22.453           0.002   6.759   2.035--22.453   0.002
  Tumor size (cm)                                                                                         
   \<3                      1.000                                                                         
   ≥3                       0.841                 0.179--3.965            0.830                           
  Distance from AV (cm)                                                                                   
   \<5                      1.000                                                                         
   ≥5                       0.386                 0.116--1.282            0.560                           
  Depth of tumor                                                                                          
   Shallow SM invasion      1.000                                                                         
   Deep SM invasion         2.839                 0.622--12.959           0.180                           
  Histology                                                                                               
   Favorable                1.000                                                                         
   Unfavorable              7.183                 0.923--55.881           0.060                           
  Lymphovascular invasion                                                                                 
   No                       1.000                                                                         
   Yes                      1.701                 0.373--7.765            0.490                           
  CEA                                                                                                     
   Normal                   1.000                                                                         
   Elevated                 4.914                 0.634--38.084           0.130                           
  Radiation therapy                                                                                       
   No                       1.000                                                                         
   Yes                      2.883                 0.780--10.659           0.110                           
  Chemotherapy                                                                                            
   No                       1.000                                                                         
   Yes                      0.945                 0.207--4.312            0.180                           

HR, hazard ratio; CI, confidence interval; TAE, transanal excision; TME, total mesorectal excision; AV, anal verge; SM, submucosal; CEA, carcinoembryonic antigen.

###### 

Univariate and multivariate analyses of local recurrence

  Variable                Univariate analysis   Multivariate analysis                                     
  ----------------------- --------------------- ----------------------- ------- -------- ---------------- -------
  Sex                                                                                                     
   Male                   1.000                                                                           
   Female                 7.844                 0.944--65.152           0.060                             
  Operation type                                                                                          
   TME                    1.000                                                 1.000                     
   TAE                    20.788                2.503--172.686          0.005   19.066   2.274--159.832   0.007
  Tumor size (cm)                                                                                         
   \<3                    1.000                                                                           
   ≥3                     0.033                 0.000--118.142          0.420                             
  Distance from AV (cm)                                                                                   
   \<5                    1.000                                                                           
   ≥5                     0.316                 0.061--1.627            0.170                             
  Depth of tumor                                                                                          
   Shallow SM invasion    1.000                                                                           
   Deep SM inv.           3.335                 0.401--27.701           0.650                             
  Histology                                                                                               
   Favorable              1.000                                                 1.000                     
   Unfavorable            12.110                1.455--100.790          0.021   6.846    0.808--57.976    0.080
  LVI                                                                                                     
   No                     1.000                                                                           
   Yes                    1.370                 0.165--11.382           0.770                             
  CEA                                                                                                     
   Normal                 1.000                                                                           
   Elevated               4.914                 0.634--38.084           0.130                             
  Radiation therapy                                                                                       
   No                     1.000                                                                           
   Yes                    1.468                 0.177--12.196           0.720                             
  Chemotherapy                                                                                            
   No                     1.000                                                                           
   Yes                    0.037                 0.000--167.320          0.440                             

HR, hazard ratio; CI, confidence interval; TME, total mesorectal excision; TAE, transanal excision; AV, anal verge; SM, submucosal; LVI, lymphovascular invasion; CEA, carcinoembryonic antigen.
